{"record_type":"pith_number_record","schema_url":"https://pith.science/schemas/pith-number/v1.json","pith_number":"pith:2020:JANLBFF7BAVHETOA4GRX2JGEQP","short_pith_number":"pith:JANLBFF7","schema_version":"1.0","canonical_sha256":"481ab094bf082a724dc0e1a37d24c483ce4ed0d5d51d79c6959deef0d979f620","source":{"kind":"arxiv","id":"2012.05301","version":2},"attestation_state":"computed","paper":{"title":"What Were They Thinking? Pharmacologic priors implicit in a choice of 3+3 dose-escalation design","license":"http://creativecommons.org/licenses/by/4.0/","headline":"","cross_cats":["q-bio.QM","stat.AP"],"primary_cat":"stat.ME","authors_text":"David C. Norris","submitted_at":"2020-12-09T20:33:38Z","abstract_excerpt":"If explicit, formal consideration of clinical pharmacology at all informs the design and conduct of modern oncology dose-finding trials, the designs themselves hardly attest to this. Yet in conducting a trial, investigators affirm that they hold reasonable expectations of participant safety - expectations that necessarily depend on beliefs about how certain pharmacologic parameters are distributed in the study population. Thus, these beliefs are implicit in a trial's presumed conformance to a community standard of safety, and may therefore to some extent be reverse-engineered from trial design"},"verification_status":{"content_addressed":true,"pith_receipt":true,"author_attested":false,"weak_author_claims":0,"strong_author_claims":0,"externally_anchored":false,"storage_verified":false,"citation_signatures":0,"replication_records":0,"graph_snapshot":true,"references_resolved":false,"formal_links_present":false},"canonical_record":{"source":{"id":"2012.05301","kind":"arxiv","version":2},"metadata":{"license":"http://creativecommons.org/licenses/by/4.0/","primary_cat":"stat.ME","submitted_at":"2020-12-09T20:33:38Z","cross_cats_sorted":["q-bio.QM","stat.AP"],"title_canon_sha256":"79204dab53ce11f4074d42d46485fd8cb9d738b041da95b9e7177354b9a9db77","abstract_canon_sha256":"9711e9783f2c75b446d10e08795b5882396ecf2b9a953282ce9aa3ca09261224"},"schema_version":"1.0"},"receipt":{"kind":"pith_receipt","key_id":"pith-v1-2026-05","algorithm":"ed25519","signed_at":"2026-07-05T02:01:55.434805Z","signature_b64":"9lPtixin/cu3BNoZKyuMOinOXO8TfEN8SPxwrA5KiPHA0Ixf/XIB33J/M368gRblVgvpc0WBjjuLIM3r7NDjAw==","signed_message":"canonical_sha256_bytes","builder_version":"pith-number-builder-2026-05-17-v1","receipt_version":"0.3","canonical_sha256":"481ab094bf082a724dc0e1a37d24c483ce4ed0d5d51d79c6959deef0d979f620","last_reissued_at":"2026-07-05T02:01:55.434381Z","signature_status":"signed_v1","first_computed_at":"2026-07-05T02:01:55.434381Z","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54"},"graph_snapshot":{"paper":{"title":"What Were They Thinking? Pharmacologic priors implicit in a choice of 3+3 dose-escalation design","license":"http://creativecommons.org/licenses/by/4.0/","headline":"","cross_cats":["q-bio.QM","stat.AP"],"primary_cat":"stat.ME","authors_text":"David C. Norris","submitted_at":"2020-12-09T20:33:38Z","abstract_excerpt":"If explicit, formal consideration of clinical pharmacology at all informs the design and conduct of modern oncology dose-finding trials, the designs themselves hardly attest to this. Yet in conducting a trial, investigators affirm that they hold reasonable expectations of participant safety - expectations that necessarily depend on beliefs about how certain pharmacologic parameters are distributed in the study population. Thus, these beliefs are implicit in a trial's presumed conformance to a community standard of safety, and may therefore to some extent be reverse-engineered from trial design"},"claims":{"count":0,"items":[],"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"source":{"id":"2012.05301","kind":"arxiv","version":2},"verdict":{"id":null,"model_set":{},"created_at":null,"strongest_claim":"","one_line_summary":"","pipeline_version":null,"weakest_assumption":"","pith_extraction_headline":""},"integrity":{"clean":true,"summary":{"advisory":0,"critical":0,"by_detector":{},"informational":0},"endpoint":"/pith/2012.05301/integrity.json","findings":[],"available":true,"detectors_run":[],"snapshot_sha256":"c28c3603d3b5d939e8dc4c7e95fa8dfce3d595e45f758748cecf8e644a296938"},"references":{"count":0,"sample":[],"resolved_work":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57","internal_anchors":0},"formal_canon":{"evidence_count":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"author_claims":{"count":0,"strong_count":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"builder_version":"pith-number-builder-2026-05-17-v1"},"aliases":[{"alias_kind":"arxiv","alias_value":"2012.05301","created_at":"2026-07-05T02:01:55.434439+00:00"},{"alias_kind":"arxiv_version","alias_value":"2012.05301v2","created_at":"2026-07-05T02:01:55.434439+00:00"},{"alias_kind":"doi","alias_value":"10.48550/arxiv.2012.05301","created_at":"2026-07-05T02:01:55.434439+00:00"},{"alias_kind":"pith_short_12","alias_value":"JANLBFF7BAVH","created_at":"2026-07-05T02:01:55.434439+00:00"},{"alias_kind":"pith_short_16","alias_value":"JANLBFF7BAVHETOA","created_at":"2026-07-05T02:01:55.434439+00:00"},{"alias_kind":"pith_short_8","alias_value":"JANLBFF7","created_at":"2026-07-05T02:01:55.434439+00:00"}],"events":[],"event_summary":{},"paper_claims":[],"inbound_citations":{"count":1,"internal_anchor_count":1,"sample":[{"citing_arxiv_id":"2507.01370","citing_title":"Dose-Escalation Trial Protocols that Extend Naturally to Admit Titration","ref_index":16,"is_internal_anchor":true}]},"formal_canon":{"evidence_count":0,"sample":[],"anchors":[]},"links":{"html":"https://pith.science/pith/JANLBFF7BAVHETOA4GRX2JGEQP","json":"https://pith.science/pith/JANLBFF7BAVHETOA4GRX2JGEQP.json","graph_json":"https://pith.science/api/pith-number/JANLBFF7BAVHETOA4GRX2JGEQP/graph.json","events_json":"https://pith.science/api/pith-number/JANLBFF7BAVHETOA4GRX2JGEQP/events.json","paper":"https://pith.science/paper/JANLBFF7"},"agent_actions":{"view_html":"https://pith.science/pith/JANLBFF7BAVHETOA4GRX2JGEQP","download_json":"https://pith.science/pith/JANLBFF7BAVHETOA4GRX2JGEQP.json","view_paper":"https://pith.science/paper/JANLBFF7","resolve_alias":"https://pith.science/api/pith-number/resolve?arxiv=2012.05301&json=true","fetch_graph":"https://pith.science/api/pith-number/JANLBFF7BAVHETOA4GRX2JGEQP/graph.json","fetch_events":"https://pith.science/api/pith-number/JANLBFF7BAVHETOA4GRX2JGEQP/events.json","actions":{"anchor_timestamp":"https://pith.science/pith/JANLBFF7BAVHETOA4GRX2JGEQP/action/timestamp_anchor","attest_storage":"https://pith.science/pith/JANLBFF7BAVHETOA4GRX2JGEQP/action/storage_attestation","attest_author":"https://pith.science/pith/JANLBFF7BAVHETOA4GRX2JGEQP/action/author_attestation","sign_citation":"https://pith.science/pith/JANLBFF7BAVHETOA4GRX2JGEQP/action/citation_signature","submit_replication":"https://pith.science/pith/JANLBFF7BAVHETOA4GRX2JGEQP/action/replication_record"}},"created_at":"2026-07-05T02:01:55.434439+00:00","updated_at":"2026-07-05T02:01:55.434439+00:00"}